Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 90 entries
Sorted by: Best Match Show Resources per page
New developments in the management of narcolepsy.

Nature and science of sleep

Abad VC, Guilleminault C.
PMID: 28424564
Nat Sci Sleep. 2017 Mar 03;9:39-57. doi: 10.2147/NSS.S103467. eCollection 2017.

Narcolepsy is a life-long, underrecognized sleep disorder that affects 0.02%-0.18% of the US and Western European populations. Genetic predisposition is suspected because of narcolepsy's strong association with HLA DQB1*06-02, and genome-wide association studies have identified polymorphisms in T-cell receptor...

Cite
Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017;9:39-57doi: 10.2147/NSS.S103467.
Abad, V. C., & Guilleminault, C. (2017). New developments in the management of narcolepsy. Nature and science of sleep, 939-57. https://doi.org/10.2147/NSS.S103467
Abad, Vivien C, and Guilleminault, Christian. "New developments in the management of narcolepsy." Nature and science of sleep vol. 9 (2017): 39-57. doi: https://doi.org/10.2147/NSS.S103467
Abad VC, Guilleminault C. New developments in the management of narcolepsy. Nat Sci Sleep. 2017 Mar 03;9:39-57. doi: 10.2147/NSS.S103467. eCollection 2017. PMID: 28424564; PMCID: PMC5344488.
Copy Download .nbib Format: NLM
Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD.

Nature and science of sleep

Wang YG, Benmedjahed K, Lambert J, Evans CJ, Hwang S, Black J, Johns MW.
PMID: 28860883
Nat Sci Sleep. 2017 Aug 14;9:201-211. doi: 10.2147/NSS.S140143. eCollection 2017.

OBJECTIVE: The aim of this study was to qualitatively evaluate concepts for incorporation into a daily diary to capture cataplexy frequency and to assess the content validity of the Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) in pediatric...

Cite
Wang YG, Benmedjahed K, Lambert J, et al. Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. Nat Sci Sleep. 2017;9:201-211doi: 10.2147/NSS.S140143.
Wang, Y. G., Benmedjahed, K., Lambert, J., Evans, C. J., Hwang, S., Black, J., & Johns, M. W. (2017). Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. Nature and science of sleep, 9201-211. https://doi.org/10.2147/NSS.S140143
Wang, Y Grace, et al. "Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD." Nature and science of sleep vol. 9 (2017): 201-211. doi: https://doi.org/10.2147/NSS.S140143
Wang YG, Benmedjahed K, Lambert J, Evans CJ, Hwang S, Black J, Johns MW. Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD. Nat Sci Sleep. 2017 Aug 14;9:201-211. doi: 10.2147/NSS.S140143. eCollection 2017. PMID: 28860883; PMCID: PMC5565379.
Copy Download .nbib Format: NLM
Diagnosis and management of central hypersomnias.

Therapeutic advances in neurological disorders

Sonka K, Susta M.
PMID: 22973425
Ther Adv Neurol Disord. 2012 Sep;5(5):297-305. doi: 10.1177/1756285612454692.

Central hypersomnias are diseases manifested in excessive daytime sleepiness (EDS) not caused by disturbed nocturnal sleep or misaligned circadian rhythms. Central hypersomnias includes narcolepsy with and without cataplexy, recurrent hypersomnia, idiopathic hypersomnia, with and without long sleep time, behaviorally...

Cite
Sonka K, Susta M. Diagnosis and management of central hypersomnias. Ther Adv Neurol Disord. 2012;5(5):297-305doi: 10.1177/1756285612454692.
Sonka, K., & Susta, M. (2012). Diagnosis and management of central hypersomnias. Therapeutic advances in neurological disorders, 5(5), 297-305. https://doi.org/10.1177/1756285612454692
Sonka, Karel, and Susta, Marek. "Diagnosis and management of central hypersomnias." Therapeutic advances in neurological disorders vol. 5,5 (2012): 297-305. doi: https://doi.org/10.1177/1756285612454692
Sonka K, Susta M. Diagnosis and management of central hypersomnias. Ther Adv Neurol Disord. 2012 Sep;5(5):297-305. doi: 10.1177/1756285612454692. PMID: 22973425; PMCID: PMC3437530.
Copy Download .nbib Format: NLM
Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Journal of clinical toxicology

Morris ME, Morse BL, Baciewicz GJ, Tessena MM, Acquisto NM, Hutchinson DJ, Dicenzo R.
PMID: 24772380
J Clin Toxicol. 2011 Nov 10;1(2):1000105. doi: 10.4172/2161-0495.1000105.

BACKGROUND AND OBJECTIVE: The purpose of the current study was to demonstrate proof-of-concept that monocarboxylate transporter (MCT) inhibition with L-lactate combined with osmotic diuresis increases renal clearance of γ-hydroxybutyrate (GHB) in human subjects. GHB is a substrate for human...

Cite
Morris ME, Morse BL, Baciewicz GJ, et al. Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study. J Clin Toxicol. 2011;1(2):1000105doi: 10.4172/2161-0495.1000105.
Morris, M. E., Morse, B. L., Baciewicz, G. J., Tessena, M. M., Acquisto, N. M., Hutchinson, D. J., & Dicenzo, R. (2011). Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study. Journal of clinical toxicology, 1(2), 1000105. https://doi.org/10.4172/2161-0495.1000105
Morris, Marilyn E, et al. "Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study." Journal of clinical toxicology vol. 1,2 (2011): 1000105. doi: https://doi.org/10.4172/2161-0495.1000105
Morris ME, Morse BL, Baciewicz GJ, Tessena MM, Acquisto NM, Hutchinson DJ, Dicenzo R. Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study. J Clin Toxicol. 2011 Nov 10;1(2):1000105. doi: 10.4172/2161-0495.1000105. PMID: 24772380; PMCID: PMC3999665.
Copy Download .nbib Format: NLM
Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate.

Neurology and therapy

Mamelak M.
PMID: 29368093
Neurol Ther. 2018 Jun;7(1):5-11. doi: 10.1007/s40120-018-0091-2. Epub 2018 Jan 24.

The high energy demands of the substantia nigra pars compacta dopaminergic (DASNc) neurons render these neurons vulnerable to degeneration. These energy demands are a function of their long and extensively arborized axons and very large number of transmitter release...

Cite
Mamelak M. Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate. Neurol Ther. 2018;7(1):5-11doi: 10.1007/s40120-018-0091-2.
Mamelak, M. (2018). Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate. Neurology and therapy, 7(1), 5-11. https://doi.org/10.1007/s40120-018-0091-2
Mamelak, Mortimer. "Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate." Neurology and therapy vol. 7,1 (2018): 5-11. doi: https://doi.org/10.1007/s40120-018-0091-2
Mamelak M. Parkinson's Disease, the Dopaminergic Neuron and Gammahydroxybutyrate. Neurol Ther. 2018 Jun;7(1):5-11. doi: 10.1007/s40120-018-0091-2. Epub 2018 Jan 24. PMID: 29368093; PMCID: PMC5990513.
Copy Download .nbib Format: NLM
Sodium Oxybate for Narcolepsy: Explaining Untoward Effects and Recommending New Approaches in Light of Prevailing Receptor Pharmacology.

The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians

VanWert AL, McCune DF, Brown KM, Bommareddy A, Manning DH, Roman CL.
PMID: 34860897
J Pharm Technol. 2014 Dec;30(6):240-243. doi: 10.1177/8755122514545518. Epub 2014 Jul 30.

No abstract available.

Cite
VanWert AL, McCune DF, Brown KM, et al. Sodium Oxybate for Narcolepsy: Explaining Untoward Effects and Recommending New Approaches in Light of Prevailing Receptor Pharmacology. J Pharm Technol. 2014;30(6):240-243doi: 10.1177/8755122514545518.
VanWert, A. L., McCune, D. F., Brown, K. M., Bommareddy, A., Manning, D. H., & Roman, C. L. (2014). Sodium Oxybate for Narcolepsy: Explaining Untoward Effects and Recommending New Approaches in Light of Prevailing Receptor Pharmacology. The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians, 30(6), 240-243. https://doi.org/10.1177/8755122514545518
VanWert, Adam L, et al. "Sodium Oxybate for Narcolepsy: Explaining Untoward Effects and Recommending New Approaches in Light of Prevailing Receptor Pharmacology." The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians vol. 30,6 (2014): 240-243. doi: https://doi.org/10.1177/8755122514545518
VanWert AL, McCune DF, Brown KM, Bommareddy A, Manning DH, Roman CL. Sodium Oxybate for Narcolepsy: Explaining Untoward Effects and Recommending New Approaches in Light of Prevailing Receptor Pharmacology. J Pharm Technol. 2014 Dec;30(6):240-243. doi: 10.1177/8755122514545518. Epub 2014 Jul 30. PMID: 34860897; PMCID: PMC5990161.
Copy Download .nbib Format: NLM
Validation of the Epworth sleepiness scale for children and adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years.

Sleep medicine

Wang YG, Menno D, Chen A, Steininger TL, Morris S, Black J, Profant J, Johns MW.
PMID: 34920345
Sleep Med. 2021 Nov 11;89:78-84. doi: 10.1016/j.sleep.2021.11.003. Epub 2021 Nov 11.

OBJECTIVE/BACKGROUND: The Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) measures daytime sleepiness, but had not previously been validated in children

Cite
Wang YG, Menno D, Chen A, et al. Validation of the Epworth sleepiness scale for children and adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years. Sleep Med. 2021;89:78-84doi: 10.1016/j.sleep.2021.11.003.
Wang, Y. G., Menno, D., Chen, A., Steininger, T. L., Morris, S., Black, J., Profant, J., & Johns, M. W. (2021). Validation of the Epworth sleepiness scale for children and adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years. Sleep medicine, 8978-84. https://doi.org/10.1016/j.sleep.2021.11.003
Wang, Y Grace, et al. "Validation of the Epworth sleepiness scale for children and adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years." Sleep medicine vol. 89 (2021): 78-84. doi: https://doi.org/10.1016/j.sleep.2021.11.003
Wang YG, Menno D, Chen A, Steininger TL, Morris S, Black J, Profant J, Johns MW. Validation of the Epworth sleepiness scale for children and adolescents (ESS-CHAD) questionnaire in pediatric patients with narcolepsy with cataplexy aged 7-16 years. Sleep Med. 2021 Nov 11;89:78-84. doi: 10.1016/j.sleep.2021.11.003. Epub 2021 Nov 11. PMID: 34920345.
Copy Download .nbib Format: NLM
Narcolepsy treatment in Sweden: An observational study.

Acta neurologica Scandinavica

Gauffin H, Fast T, Komkova A, Berntsson S, Boström I, Landtblom AM.
PMID: 34611886
Acta Neurol Scand. 2022 Feb;145(2):185-192. doi: 10.1111/ane.13532. Epub 2021 Oct 06.

OBJECTIVES: To describe the pharmacological treatments (2005-2017) and the healthcare utilization (1997-2016) for patients with narcolepsy in Sweden in order to create a framework for future organizational and economic analyses.MATERIAL & METHODS: Patients of all ages with a diagnosis...

Cite
Gauffin H, Fast T, Komkova A, et al. Narcolepsy treatment in Sweden: An observational study. Acta Neurol Scand. 2021;145(2):185-192doi: 10.1111/ane.13532.
Gauffin, H., Fast, T., Komkova, A., Berntsson, S., Boström, I., & Landtblom, A. M. (2022). Narcolepsy treatment in Sweden: An observational study. Acta neurologica Scandinavica, 145(2), 185-192. https://doi.org/10.1111/ane.13532
Gauffin, Helena, et al. "Narcolepsy treatment in Sweden: An observational study." Acta neurologica Scandinavica vol. 145,2 (2022): 185-192. doi: https://doi.org/10.1111/ane.13532
Gauffin H, Fast T, Komkova A, Berntsson S, Boström I, Landtblom AM. Narcolepsy treatment in Sweden: An observational study. Acta Neurol Scand. 2022 Feb;145(2):185-192. doi: 10.1111/ane.13532. Epub 2021 Oct 06. PMID: 34611886.
Copy Download .nbib Format: NLM
Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF.
PMID: 34743790
J Clin Sleep Med. 2021 Sep 01;17(9):1895-1945. doi: 10.5664/jcsm.9326.

INTRODUCTION: This systematic review provides supporting evidence for the accompanying clinical practice guideline on the treatment of central disorders of hypersomnolence in adults and children. The review focuses on prescription medications with U.S. Food & Drug Administration approval and...

Cite
Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021;17(9):1895-1945doi: 10.5664/jcsm.9326.
Maski, K., Trotti, L. M., Kotagal, S., Robert Auger, R., Swick, T. J., Rowley, J. A., Hashmi, S. D., & Watson, N. F. (2021). Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 17(9), 1895-1945. https://doi.org/10.5664/jcsm.9326
Maski, Kiran, et al. "Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment." Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine vol. 17,9 (2021): 1895-1945. doi: https://doi.org/10.5664/jcsm.9326
Maski K, Trotti LM, Kotagal S, Robert Auger R, Swick TJ, Rowley JA, Hashmi SD, Watson NF. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment. J Clin Sleep Med. 2021 Sep 01;17(9):1895-1945. doi: 10.5664/jcsm.9326. PMID: 34743790; PMCID: PMC8636345.
Copy Download .nbib Format: NLM
Disrupted nighttime sleep and sleep instability in narcolepsy.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Maski K, Mignot E, Plazzi G, Dauvilliers Y.
PMID: 34463249
J Clin Sleep Med. 2021 Aug 31; doi: 10.5664/jcsm.9638. Epub 2021 Aug 31.

STUDY OBJECTIVES: This review aimed to summarize current knowledge about disrupted nighttime sleep (DNS) and sleep instability in narcolepsy, including self-reported and objective assessments, potential causes of sleep instability, health consequences and functional burden, and management.METHODS: One hundred and...

Cite
Maski K, Mignot E, Plazzi G, et al. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2021;doi: 10.5664/jcsm.9638.
Maski, K., Mignot, E., Plazzi, G., & Dauvilliers, Y. (2021). Disrupted nighttime sleep and sleep instability in narcolepsy. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, . https://doi.org/10.5664/jcsm.9638
Maski, Kiran, et al. "Disrupted nighttime sleep and sleep instability in narcolepsy." Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine vol. (2021). doi: https://doi.org/10.5664/jcsm.9638
Maski K, Mignot E, Plazzi G, Dauvilliers Y. Disrupted nighttime sleep and sleep instability in narcolepsy. J Clin Sleep Med. 2021 Aug 31; doi: 10.5664/jcsm.9638. Epub 2021 Aug 31. PMID: 34463249.
Copy Download .nbib Format: NLM
Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.

The Lancet. Neurology

Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Šonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK.
PMID: 34942138
Lancet Neurol. 2022 Jan;21(1):53-65. doi: 10.1016/S1474-4422(21)00368-9.

BACKGROUND: Idiopathic hypersomnia is a central hypersomnolence disorder mainly characterised by excessive daytime sleepiness, with prolonged night-time sleep and pronounced sleep inertia. Until August, 2021, no medication had regulatory approval for the treatment of idiopathic hypersomnia. This study aimed...

Cite
Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, et al. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022;21(1):53-65doi: 10.1016/S1474-4422(21)00368-9.
Dauvilliers, Y., Arnulf, I., Foldvary-Schaefer, N., Morse, A. M., Šonka, K., Thorpy, M. J., Mignot, E., Chandler, P., Parvataneni, R., Black, J., Sterkel, A., Chen, D., Skobieranda, F., & Bogan, R. K. (2022). Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. The Lancet. Neurology, 21(1), 53-65. https://doi.org/10.1016/S1474-4422(21)00368-9
Dauvilliers, Yves, et al. "Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study." The Lancet. Neurology vol. 21,1 (2022): 53-65. doi: https://doi.org/10.1016/S1474-4422(21)00368-9
Dauvilliers Y, Arnulf I, Foldvary-Schaefer N, Morse AM, Šonka K, Thorpy MJ, Mignot E, Chandler P, Parvataneni R, Black J, Sterkel A, Chen D, Skobieranda F, Bogan RK. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study. Lancet Neurol. 2022 Jan;21(1):53-65. doi: 10.1016/S1474-4422(21)00368-9. PMID: 34942138.
Copy Download .nbib Format: NLM
Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma.

Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine

Rossi S, Asioli GM, Rizzo G, Sallemi G, Moresco M, Franceschini C, Pizza F, Plazzi G.
PMID: 34170236
J Clin Sleep Med. 2021 Dec 01;17(12):2557-2560. doi: 10.5664/jcsm.9496.

Narcolepsy type 1 results from probable autoimmune disruption of hypothalamic hypocretinergic neurons. Secondary narcolepsy can occur as a result of other conditions affecting the central nervous system, including limbic paraneoplastic encephalitis. We report the case of a 19-year-old patient...

Cite
Rossi S, Asioli GM, Rizzo G, et al. Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma. J Clin Sleep Med. 2021;17(12):2557-2560doi: 10.5664/jcsm.9496.
Rossi, S., Asioli, G. M., Rizzo, G., Sallemi, G., Moresco, M., Franceschini, C., Pizza, F., & Plazzi, G. (2021). Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 17(12), 2557-2560. https://doi.org/10.5664/jcsm.9496
Rossi, Simone, et al. "Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma." Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine vol. 17,12 (2021): 2557-2560. doi: https://doi.org/10.5664/jcsm.9496
Rossi S, Asioli GM, Rizzo G, Sallemi G, Moresco M, Franceschini C, Pizza F, Plazzi G. Onset of narcolepsy type 1 in a paraneoplastic encephalitis associated with a thymic seminoma. J Clin Sleep Med. 2021 Dec 01;17(12):2557-2560. doi: 10.5664/jcsm.9496. PMID: 34170236.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 90 entries